1. Introduction {#sec1-nutrients-12-01573}
===============

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting about 5% of children and 2.5% of adults worldwide. It is characterized by dysregulated cognition and behaviors, resulting in inattention, excessive motor activity, and impulsivity \[[@B1-nutrients-12-01573]\].

Drug treatments for ADHD mainly act to potentiate the action of catecholamines, which are neurotransmitters involved in the prefrontal cortex responsible for the maintenance of attention and cognitive control \[[@B2-nutrients-12-01573]\].

Stimulants, the first choice for ADHD drug treatment, include methylphenidate that inhibits dopamine reuptake and amphetamines that inhibit dopamine and noradrenaline reuptake and increase dopamine release. Atomoxetine is the most common non-stimulant medication for ADHD and acts by inhibiting norepinephrine reuptake \[[@B3-nutrients-12-01573]\].

The efficacy of stimulants and non-stimulants in reducing ADHD symptoms is well documented in children and adults \[[@B4-nutrients-12-01573],[@B5-nutrients-12-01573]\]. However, the tolerability of these drugs can be scarce in some patients, warranting treatment interruption. At least 10--30% of children with ADHD may not benefit from these medications due to non-response or adverse effects \[[@B6-nutrients-12-01573],[@B7-nutrients-12-01573]\] such as decreased appetite, insomnia, stomachache, headache, weight loss (potentially leading to growth retardation), tics, increases in blood pressure, and potential abuse or misuse \[[@B8-nutrients-12-01573]\]. Although less effective than stimulants, non-stimulant medication are first choice treatments for individuals with co-diagnoses including tic, mood, and anxiety disorders \[[@B3-nutrients-12-01573]\]. However, atomoxetine use has been associated with increased risk of suicidal behavior in youths \[[@B9-nutrients-12-01573]\].

ADHD is a multifactorial disorder, in which genetic and biological factors have important roles; ADHD symptomatology expression is also influenced by environmental factors, like nutrition \[[@B10-nutrients-12-01573]\]. To explain the role of nutritional deficiencies, to which part of non-responses to medications have been imputed, several studies focused on supplementation approaches, as alternative or additional therapies.

Within this research area, many studies have focused on macronutrient supplementations, mainly polyunsaturated fatty acids (PUFAs), that are precursors of eicosanoids and are relevant components of cell membranes and of phospholipids. PUFAs influence the quality of growth and development \[[@B11-nutrients-12-01573]\]. Research about PUFAs adjunctive treatments for ADHD did not produce convincing evidence, probably due to the heterogeneity of methods and doses administered \[[@B12-nutrients-12-01573],[@B13-nutrients-12-01573]\].

Few studies have also examined the role of other macronutrients such as peptides and amino acids derivatives, which can act as metabolic adjuvants. In particular, there are experimental trials using Acetyl-L-carnitine (ALC) to optimize mitochondrial fatty acid oxidation. It has been reported that ALC treatment increased sodium levels in the cingulate cortex and the 5HIAA/5HT ratio in both cingulate cortex and medial frontal cortex in adolescent impulsive rats \[[@B14-nutrients-12-01573]\] and it could have a link with hyperactivity and impulsivity symptoms in children with ADHD \[[@B15-nutrients-12-01573]\]. L-carnosine (a dipeptide composed of β-alanine and l-histidine) is known as an antiaging antioxidant and neuroprotective compound, and it is found highly concentrated in brain tissues \[[@B16-nutrients-12-01573]\]. L-carnosine has also been associated to ADHD symptoms \[[@B17-nutrients-12-01573]\]: it accumulates in the subfrontal cortex and may enhance frontal lobe functions \[[@B18-nutrients-12-01573]\], interesting for ADHD research. Lastly, Phosphatidylserine (PS), a naturally occurring phospholipid, modulates the activity of receptors, enzymes, ion channels and signaling molecules, and contributes to regulate membrane fluidity \[[@B19-nutrients-12-01573]\]. PS has been shown to counteract the stress-induced activation of the hypothalamic-pituitary-adrenal axis \[[@B20-nutrients-12-01573]\]; it has been involved in ADHD symptomatology and short-term auditory memory \[[@B21-nutrients-12-01573]\].

Other studies have investigated the role of various micronutrients (e.g., oligoelements, vitamins, minerals) as alternative or supporting non-pharmacological treatment for ADHD.

Vitamin D deficiency is relevant in the pathogenesis of psychiatric disorders including autism, depression, schizophrenia, and ADHD \[[@B22-nutrients-12-01573],[@B23-nutrients-12-01573],[@B24-nutrients-12-01573]\]. Vitamin D can act on central dopamine levels via different mechanisms, including calcium transition, antioxidant properties and gene expression \[[@B25-nutrients-12-01573]\].

Another micronutrient linked to dopamine metabolism is zinc, a cofactor of many metalloenzymes and metal--enzyme complexes \[[@B26-nutrients-12-01573]\]. Studies conducted on animals and humans associated zinc deficiency and hyperactivity \[[@B27-nutrients-12-01573],[@B28-nutrients-12-01573]\]. Researchers also focused on broad-spectrum supplementation approaches, highlighting the efficacy of minerals and vitamins combinations \[[@B29-nutrients-12-01573]\].

Complementary or alternative medicine approaches propose herbal extracts for children with ADHD. However, these studies have not yet produced structured evidence \[[@B30-nutrients-12-01573]\].

Lastly, an interesting hypothesis is that gut microbiota and probiotics could influence brain activity and behaviors and psychiatric symptoms \[[@B31-nutrients-12-01573]\]. In rodent studies, modifications of gut microbiota are associated with cerebral signals modification, in cortical and subcortical regions, linked to affective and sensory functions \[[@B32-nutrients-12-01573]\]. Evidence in humans is preliminary; however, chronic intake of probiotics is associated in healthy adults with altered brain connectivity during affective and attentive tasks \[[@B32-nutrients-12-01573]\].

Given the number and heterogeneity of studies conducted on nutritional supplementation in ADHD, the present review aims at offering a systematization for the results of studies conducted from January 2010 to March 2020 and evaluating the efficacy of non-pharmacological dietary supplementations in ADHD.

We defined the present review as "critical" to highlight our aim to offer clinicians an analytical and up-to-date point of view in the clinical management of children and adolescents with ADHD, specifically in a nutritional supplementation framework alone or in combination with pharmacological treatment. Moreover, this review did not have a systematic or quantitative objective.

2. Materials and Methods {#sec2-nutrients-12-01573}
========================

The present review is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) \[[@B33-nutrients-12-01573]\]. We searched PubMed from January 2010 to March 2020 using the following string: (probiotic OR prebiotic OR vitamin OR mineral OR phytonutrient OR amino acid OR supplementation OR non-pharmacological) AND (ADHD OR attention deficit hyperactivity disorder) NOT review \[All Fields\] NOT adult NOT infant. The search manually completed with relevant articles. We included randomized controlled trials involving children and adolescents with ADHD receiving non-pharmacological supplementation. We focused on studies addressing cognitive or behavioral outcomes; we excluded papers not written in English, researches addressing other diagnoses than ADHD, studies with no administration of non-pharmacological supplementations, studies that did not report behavioral/cognitive outcomes, and studies on preschool or adult subjects. Specifically, our search did not include infants (\<5 years) given ADHD onset which typically corresponds to school age \[[@B1-nutrients-12-01573]\]. Moreover, since this review aim was to offer evidences regarding clinical management of children and adolescents with ADHD, we decided to exclude adults in the PubMed search.

3. Results {#sec3-nutrients-12-01573}
==========

Our search found 414 articles. After title and abstract screening, articles retained were 44; we excluded two articles after full text review. In total, 42 articles are included in the present review. The PRISMA flow chart is shown in [Figure 1](#nutrients-12-01573-f001){ref-type="fig"}.

In the following text and tables, results are presented according to supplementation categories as follows:PUFAs;peptides and amino acids derivatives;single micronutrient (Zinc or Vitamin D);micronutrients mix;plant extracts or herbal supplementations;probiotics.

3.1. PUFAs {#sec3dot1-nutrients-12-01573}
----------

### 3.1.1. Methodologies {#sec3dot1dot1-nutrients-12-01573}

In total, 20 studies focused on supplementation with PUFAs \[[@B34-nutrients-12-01573],[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B40-nutrients-12-01573],[@B41-nutrients-12-01573],[@B42-nutrients-12-01573],[@B43-nutrients-12-01573],[@B44-nutrients-12-01573],[@B45-nutrients-12-01573],[@B46-nutrients-12-01573],[@B47-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B50-nutrients-12-01573],[@B51-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\] (see [Table 1](#nutrients-12-01573-t001){ref-type="table"}a): fourteen were on patients without comorbidities \[[@B34-nutrients-12-01573],[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B38-nutrients-12-01573],[@B40-nutrients-12-01573],[@B41-nutrients-12-01573],[@B42-nutrients-12-01573],[@B43-nutrients-12-01573],[@B44-nutrients-12-01573],[@B45-nutrients-12-01573],[@B46-nutrients-12-01573],[@B47-nutrients-12-01573],[@B50-nutrients-12-01573],[@B53-nutrients-12-01573]\], two with oppositional defiant disorder (ODD) \[[@B35-nutrients-12-01573],[@B39-nutrients-12-01573]\], and four with various co-diagnoses, such as specific learning disorder, ODD, conduct disorder, tic disorder, anxiety, Tourette syndrome, or psychomotor difficulties \[[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B51-nutrients-12-01573],[@B52-nutrients-12-01573]\]. Two researches \[[@B42-nutrients-12-01573],[@B43-nutrients-12-01573]\] include very small samples.

These studies supplemented with various omega-3 fatty acids. In total, 18 studies provided docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) \[[@B34-nutrients-12-01573],[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B40-nutrients-12-01573],[@B41-nutrients-12-01573],[@B42-nutrients-12-01573],[@B44-nutrients-12-01573],[@B45-nutrients-12-01573],[@B46-nutrients-12-01573],[@B47-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B50-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\], one study provided alpha linolenic acid (ALA) \[[@B43-nutrients-12-01573]\], and one study did not specify which omega-3 was used. Three studies supplemented omega-6: one used gamma-linolenic acid (GLA) \[[@B36-nutrients-12-01573]\], while two did not specify which omega-6 was used \[[@B35-nutrients-12-01573],[@B51-nutrients-12-01573]\]. One study provided, together with EPA and DHA, conjugated linoleic acid (CLA), a precursor of a distinct family of PUFAs (both omega-3 and omega-6) \[[@B47-nutrients-12-01573]\]. In two linked studies, authors prescribed linoleic acid (LA) omega-6 as a control condition compared to two omega-3 groups \[[@B48-nutrients-12-01573],[@B49-nutrients-12-01573]\]. Seven studies added vitamins to EPA and DHA \[[@B40-nutrients-12-01573],[@B44-nutrients-12-01573],[@B47-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\]; each of the seven provided vitamin E, whereas in Cornu et al. added vitamins A and D \[[@B40-nutrients-12-01573]\]. Six studies allowed pharmacotherapy concomitant with PUFA supplementation \[[@B34-nutrients-12-01573],[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B50-nutrients-12-01573],[@B52-nutrients-12-01573]\], while two added to EPA and DHA supplementation with PS \[[@B46-nutrients-12-01573]\] or docosapentaenoic acid \[[@B52-nutrients-12-01573]\]. Although PUFAs represent now the most used supplementation in this field, there is too much heterogeneity around the specific PUFAs used. It remains unclear if the efficacy of results depend on individual type of omega-3/6 or the whole of macronutrients.

Randomization between treatment and placebo groups is equal, except for one study \[[@B46-nutrients-12-01573]\], but there is still too much heterogeneity around the number of treatment groups.

Concerning outcomes, several studies used both multiple questionnaires/ratings \[[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B41-nutrients-12-01573],[@B44-nutrients-12-01573],[@B46-nutrients-12-01573]\] and cognitive tasks \[[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B40-nutrients-12-01573],[@B42-nutrients-12-01573],[@B43-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\] and only one includes fMRI assessment \[[@B38-nutrients-12-01573]\]. However, other many studies kept in consideration only one questionnaire \[[@B34-nutrients-12-01573],[@B35-nutrients-12-01573],[@B45-nutrients-12-01573],[@B47-nutrients-12-01573],[@B50-nutrients-12-01573],[@B51-nutrients-12-01573]\], as a result future researches could integrate better outcome measures.

### 3.1.2. Results {#sec3dot1dot2-nutrients-12-01573}

Regarding results, 13 studies highlighted various improvements related to PUFAs supplementation \[[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B41-nutrients-12-01573],[@B44-nutrients-12-01573],[@B45-nutrients-12-01573],[@B46-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B51-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\]. Six of those used EPA and DHA combinations \[[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B41-nutrients-12-01573],[@B45-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573]\], three used unspecified omega3 + omega6 combinations \[[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B51-nutrients-12-01573]\], three added vitamin E to the omega3 formula \[[@B44-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\], and one study prescribed PS together with omega3 \[[@B46-nutrients-12-01573]\]. In these studies, ameliorations were not related to specific cognitive or behavioral domains. The remaining seven studies \[[@B34-nutrients-12-01573],[@B40-nutrients-12-01573],[@B42-nutrients-12-01573],[@B43-nutrients-12-01573],[@B47-nutrients-12-01573],[@B49-nutrients-12-01573],[@B50-nutrients-12-01573]\] did not find positive results linked to PUFAs supplementation. Future investigations with homogeneous methodologies are needed to clarify the reason of non-significant results or could better specify the role of PUFAs supplementation on ADHD symptoms.

3.2. Peptides and Amino Acids Derivatives {#sec3dot2-nutrients-12-01573}
-----------------------------------------

### 3.2.1. Methodologies {#sec3dot2dot1-nutrients-12-01573}

We identified three studies \[[@B15-nutrients-12-01573],[@B17-nutrients-12-01573],[@B21-nutrients-12-01573]\] using Acetyl-L-carnitine (ALC), l-carnosine, and PS ([Table 1](#nutrients-12-01573-t001){ref-type="table"}b). It is not possible to depict a systematic comparison of those studies, given the heterogeneous supplementation approaches. Specifically, two works \[[@B15-nutrients-12-01573],[@B17-nutrients-12-01573]\] compared subjects who tok a placebo to a group that took supplementation as an add-on to MPH. On the contrary, one study \[[@B21-nutrients-12-01573]\] used PS alone in the active treatment group and placebo in control group. All studies comprised uniform samples, except Ghajar et al. \[[@B17-nutrients-12-01573]\], who also included children with ODD and applied equal randomization in treatment and placebo groups. Two studies \[[@B15-nutrients-12-01573],[@B17-nutrients-12-01573]\] considered similar outcome measures, including parent and teacher questionnaires regarding children's behavioral and cognitive symptoms. Hirayama et al. \[[@B21-nutrients-12-01573]\] used a go/no-go task and ADHD diagnostic criteria. Although these studies focused on different supplementations, they applied similar methodologies, especially regarding sample, randomization, and outcomes. The use of neuropsychological and physiological parameters could be improved and integrated to better understand response to treatment mechanisms. Moreover, future researches could address PS efficacy as an add-on to MPH.

### 3.2.2. Results {#sec3dot2dot2-nutrients-12-01573}

Regarding these studies results, ALC alone did not improve ADHD symptoms \[[@B15-nutrients-12-01573]\], but it reduced adverse effects when taken in addition to MPH. Moreover, l-carnosine seemed to improve behavioral problems according to parents \[[@B17-nutrients-12-01573]\]. PS had effects on ADHD symptoms, short-term auditory memory, and cognitive tasks \[[@B21-nutrients-12-01573]\]. In conclusion, l-carnosine and PS seem to have some effects on ADHD symptoms or cognitive domains but it remains unclear their specific role and mechanisms of action.

3.3. Single Micronutrient (Zinc or Vitamin D) {#sec3dot3-nutrients-12-01573}
---------------------------------------------

### 3.3.1. Methodologies {#sec3dot3dot1-nutrients-12-01573}

Some studies tested zinc \[[@B54-nutrients-12-01573],[@B55-nutrients-12-01573],[@B56-nutrients-12-01573]\] or vitamin D \[[@B25-nutrients-12-01573],[@B57-nutrients-12-01573],[@B58-nutrients-12-01573]\] ([Table 1](#nutrients-12-01573-t001){ref-type="table"}c). Zinc was used as sulfate \[[@B55-nutrients-12-01573],[@B56-nutrients-12-01573]\] or glycinate \[[@B54-nutrients-12-01573]\] and vitamin D as generic \[[@B25-nutrients-12-01573]\] or D3 \[[@B57-nutrients-12-01573],[@B58-nutrients-12-01573]\]. All studies provided micronutrients in addition to MPH \[[@B25-nutrients-12-01573],[@B55-nutrients-12-01573],[@B56-nutrients-12-01573],[@B57-nutrients-12-01573],[@B58-nutrients-12-01573]\] or dextroamphetamine \[[@B54-nutrients-12-01573]\]. Moreover, only Arnold et al. \[[@B54-nutrients-12-01573]\] compared the effects of micronutrients (and no pharmacological treatment) with placebo. All studies except two \[[@B54-nutrients-12-01573],[@B58-nutrients-12-01573]\] included patients without comorbidity. Each study applied equal randomization between groups, even if the number of subjects was low \[e.g., 58\]. These works used similar methodologies, but several studies \[[@B25-nutrients-12-01573],[@B55-nutrients-12-01573],[@B57-nutrients-12-01573],[@B58-nutrients-12-01573]\] used only parent-ratings as outcome measure.

### 3.3.2. Results {#sec3dot3dot2-nutrients-12-01573}

A link between zinc consumption and attention improvement was found in two studies \[[@B55-nutrients-12-01573],[@B56-nutrients-12-01573]\]: zinc treatment improved inattention scores on parent questionnaires \[[@B55-nutrients-12-01573]\] and had effects on attention deficit disorder subtype of ADHD \[[@B56-nutrients-12-01573]\]. One study \[[@B54-nutrients-12-01573]\] did not find significant differences between zinc supplementation and placebo in the outcome measures; however, children taking zinc supplementation in addition to dextroamphetamine showed better drug dose optimization. All studies regarding vitamin D supplementation highlighted positive outcomes on parent-rated behavioral indexes or ADHD symptoms \[[@B25-nutrients-12-01573],[@B57-nutrients-12-01573],[@B58-nutrients-12-01573]\].

3.4. Micronutrients Mix {#sec3dot4-nutrients-12-01573}
-----------------------

### 3.4.1. Methodologies {#sec3dot4dot1-nutrients-12-01573}

Several studies focused on broad combinations of vitamins and minerals \[[@B59-nutrients-12-01573],[@B60-nutrients-12-01573],[@B61-nutrients-12-01573],[@B62-nutrients-12-01573],[@B63-nutrients-12-01573]\] ([Table 1](#nutrients-12-01573-t001){ref-type="table"}d). One used a mixture of vitamin D and magnesium \[[@B60-nutrients-12-01573]\], two provided "daily essential nutrient formula", which contained 13 vitamins, 17 minerals, and 4 amino acids \[[@B59-nutrients-12-01573],[@B61-nutrients-12-01573]\]. The remaining studies represent further analyses \[[@B63-nutrients-12-01573]\] and follow-up research \[[@B62-nutrients-12-01573]\] of the Rucklidge et al. paper \[[@B61-nutrients-12-01573]\]. All studies were comprised of children with several comorbidities and applied equal randomization between groups. All studies used multiple ratings, except for Hemamy et al. \[[@B60-nutrients-12-01573]\], and one work using magnetic resonance imaging (MRI) data as an outcome (however, this last did not find any significant effect) \[[@B59-nutrients-12-01573]\].

### 3.4.2. Results {#sec3dot4dot2-nutrients-12-01573}

These studies highlighted improvements in several behavioral, emotional, and cognitive ADHD symptoms. Furthermore, the follow-up study \[[@B62-nutrients-12-01573]\] offers additional evidences regarding possible efficacy of micronutrients mix. However, these studies are characterized by low numerosity and high heterogeneity of samples and treatments.

3.5. Plant Extracts or Herbal Supplementations {#sec3dot5-nutrients-12-01573}
----------------------------------------------

### 3.5.1. Methodologies {#sec3dot5dot1-nutrients-12-01573}

Seven studies focused on plant or herbal extracts containing a mix of micronutrients, vitamins, and macronutrients ([Table 1](#nutrients-12-01573-t001){ref-type="table"}e). It is not possible to depict a systematic comparison of those studies, given the heterogeneous supplementation approaches. Specifically, one work used Ginkgo biloba plant extract as an add-on to MPH \[[@B69-nutrients-12-01573]\]. Others examined the efficacy of an herbal compound \[[@B64-nutrients-12-01573]\], Korean red ginseng (KRG) \[[@B65-nutrients-12-01573]\] or tocotrienol-rich fractions \[[@B70-nutrients-12-01573]\], as a single treatment compared to placebo, ningdong granule \[[@B66-nutrients-12-01573]\], sweet almond syrup \[[@B67-nutrients-12-01573]\], or Ginkgo biloba \[[@B68-nutrients-12-01573]\], compared to MPH. These studies focused on patients with ADHD symptoms without comorbidities and they applied an equal randomization, except for one work \[[@B64-nutrients-12-01573]\]. Each study used multiple ratings as outcomes, one of which \[[@B65-nutrients-12-01573]\] considered neurophysiological assessment and another cognitive tasks measures \[[@B64-nutrients-12-01573]\].

### 3.5.2. Results {#sec3dot5dot2-nutrients-12-01573}

All but two studies \[[@B68-nutrients-12-01573],[@B70-nutrients-12-01573]\] found beneficial effects related to supplementation, in terms of improved symptomatology and/or less adverse effects as compared to MPH. Improvement in attention indexes was found in studies using a blend of herbs \[[@B64-nutrients-12-01573]\], Korean red ginseng \[[@B65-nutrients-12-01573]\], and Ginkgo biloba as an add-on to MPH \[[@B69-nutrients-12-01573]\]. Parent-, teacher-, or clinician-rated behavioral improvement was reported with KRG \[[@B65-nutrients-12-01573]\], ningdong granule \[[@B66-nutrients-12-01573]\], sweet almond syrup \[[@B67-nutrients-12-01573]\], and Ginkgo biloba as an add-on to MPH \[[@B69-nutrients-12-01573]\]. No adverse effects of supplementations were highlighted except for one study that reported increased appetite with sweet almond syrup \[[@B67-nutrients-12-01573]\], whereas half of the studies reported adverse effects of MPH \[[@B66-nutrients-12-01573],[@B67-nutrients-12-01573],[@B68-nutrients-12-01573]\]. One study \[[@B65-nutrients-12-01573]\] showed that KRG reduced the electroencephalography theta/beta ratio, a marker of cognitive processing capacity, significantly more than placebo. These results are heterogeneous and preliminary, and thus future homogeneous investigations that consider physiological parameters could offer more systematic evidences regarding herbal or extract supplementations. Furthermore, conflicting results \[e.g., 68--69\] between identical supplementation may be due to the different objectives: in one case authors aimed at comparing effects of supplementation with MPH \[[@B68-nutrients-12-01573]\], in the other case effects of MPH and non-pharmacological treatment together were compared to placebo \[[@B69-nutrients-12-01573]\].

3.6. Probiotics: Methodologies and Results {#sec3dot6-nutrients-12-01573}
------------------------------------------

Only one paper focused on probiotics supplementation, through a different study design compared to the other reviewed studies \[[@B71-nutrients-12-01573]\] ([Table 1](#nutrients-12-01573-t001){ref-type="table"}f). A six-months-lasting probiotic supplementation was administered soon after childbirth and a follow-up assessment was conducted after 13 years. The quantity of Bifidobacterium species bacteria in the feces of children later diagnosed with ADHD or Asperger syndrome was found to be lower as compared to healthy children. ADHD or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (*p* = 0.008). This last study offers preliminary suggestions regarding probiotics supplementation as a preventive treatment, however further randomized clinical trials are needed to offer more systematic evidence regarding this treatment efficacy.

[Figure 2](#nutrients-12-01573-f002){ref-type="fig"} summarizes the main findings reported by the included works regarding nutritional supplementations on ADHD behavioral or cognitive symptoms; the vertical axis indicates the number of studies.

4. Discussion {#sec4-nutrients-12-01573}
=============

We investigated the recent literature about the efficacy of non-pharmacological treatments for ADHD in children and adolescents, alone or in combination with pharmacological treatment.

4.1. Discussion of Methodologies {#sec4dot1-nutrients-12-01573}
--------------------------------

It is relevant that nearly half of the reviewed studies used supplementation with PUFA (mostly EPA and DHA as omega3 PUFAs and, for some, omega6; see [Table 1](#nutrients-12-01573-t001){ref-type="table"}a). This supplementation approach could be linked to previous evidence suggesting the involvement of lower blood levels of DHA in children and adolescents with ADHD \[[@B12-nutrients-12-01573]\].

The other reviewed studies addressed the efficacy of peptides and amino acids derivatives ([Table 1](#nutrients-12-01573-t001){ref-type="table"}b), micronutrients (alone or in combination; see [Table 1](#nutrients-12-01573-t001){ref-type="table"}c,d), and plant or herbal extracts ([Table 1](#nutrients-12-01573-t001){ref-type="table"}e); one study investigated the association between early-life probiotics supplementation and ADHD or Asperger syndrome diagnoses at puberty ([Table 1](#nutrients-12-01573-t001){ref-type="table"}f). These supplementation approaches are less frequently reported in the scientific literature as compared to PUFA supplementation.

Each reviewed study used different combinations and doses of drugs and/or non-pharmacological supplementations. Therefore, it is not possible to draw systematic conclusions on optimal type or dose of compound that could be useful in the treatment of ADHD symptomatology.

Regarding outcome measures, [Table 2](#nutrients-12-01573-t002){ref-type="table"} depicts a summary of sources of information that were considered in the reviewed studies. [Table 2](#nutrients-12-01573-t002){ref-type="table"} highlights the need to consider homogeneous outcome variables in future research to obtain more systematic evidence related to the same outcomes. Moreover, objective neurophysiological outcomes should be more consistently evaluated together with clinical evidence.

4.2. Discussion of Results {#sec4dot2-nutrients-12-01573}
--------------------------

The majority of reviewed papers reported improvements but no specific effect of different supplements was found, thus suggesting a non-specific beneficial influence of micro- and macro-nutrients on a broad spectrum of functions and symptoms. A possible explanation of this result could be ascribed to general environmental and dietary influences that have been previously associated to the severity of ADHD symptoms in children and adolescents, such as low socioeconomic status, parents' education, and unhealthy diet \[[@B72-nutrients-12-01573],[@B73-nutrients-12-01573]\]. In this framework, it is still unclear whether ADHD onset and persistence over time represent the cause or the effect of unhealthy dietary patterns that could lead to nutritional deficits \[[@B72-nutrients-12-01573],[@B73-nutrients-12-01573]\]. In any case, this review suggests that non-pharmacological supplementation, prescribed on the basis of individual nutritional deficiencies, could constitute a valid clinical path. It is not clear whether supplementation has a role for patients with no dietary imbalance. Moreover, the substances that are contained in various supplementations could benefit brain functioning but may also influence overall physiological functioning in children and adolescents, given a non-specific effect of these compounds. Clinicians should support alternative or additional treatment options only after appropriate blood tests and medical examinations.

In any case, the supplementation approach seems to be valid in combination with pharmacological treatment, as highlighted by positive results of MPH combination with PUFAs \[[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B52-nutrients-12-01573],[@B56-nutrients-12-01573]\], peptides or amino acid derivatives \[[@B15-nutrients-12-01573],[@B17-nutrients-12-01573]\], zinc \[[@B55-nutrients-12-01573],[@B56-nutrients-12-01573]\], vitamin D \[[@B25-nutrients-12-01573],[@B57-nutrients-12-01573],[@B58-nutrients-12-01573]\], vitamin D and magnesium \[[@B60-nutrients-12-01573]\], and sweet almond syrup \[[@B67-nutrients-12-01573]\]. In these studies, ameliorations were found in behavioral symptoms as reported by parents and clinicians, together with less adverse events compared to pharmacotherapy alone. Hence, drugs and ad hoc nutritional supplementation could represent a valid therapeutic approach.

Other studies focused on children and adolescents who were not under pharmacological treatment for reasons including low compliance, adverse effects or non-response. This second group of studies found mixed results, in terms of finding beneficial effects of supplementation alone and of finding no effect at all. However, the majority of these studies reported a beneficial effect of supplements over placebo.

Specifically, 8 out of 14 studies regarding PUFA supplementation alone found symptoms amelioration over placebo in attention, psychosocial functioning, emotional problems, behavior as reported by parents and teachers, and working memory \[[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B41-nutrients-12-01573],[@B44-nutrients-12-01573],[@B45-nutrients-12-01573],[@B46-nutrients-12-01573],[@B51-nutrients-12-01573],[@B53-nutrients-12-01573]\]. The only study addressing phosphatidylserine supplementation found positive effects of treatment over placebo in behavioral and cognitive symptomatology as reported by clinicians and through a go/no-go computerized task \[[@B21-nutrients-12-01573]\]. However, one study prescribed zinc supplementation against placebo and found no improvement in behavior, memory, or attention \[[@B54-nutrients-12-01573]\]. Five studies used plant or herbal extracts versus placebo. Two found significant beneficial effects of a patented blend of herbs (compound herbal preparation) and Korean red ginseng on attention and symptomatology as reported by clinicians \[[@B64-nutrients-12-01573],[@B65-nutrients-12-01573]\]. Two studies found similar effects of ningdong granule or sweet almond syrup as compared to MPH treatment in behavioral measures reported by parents and teachers, with fewer side effects related to herbal supplementation than MPH \[[@B66-nutrients-12-01573],[@B67-nutrients-12-01573]\]. Lastly, one study reported greater parent- and teacher-rated behavioral amelioration effects of MPH as compared to Ginkgo biloba supplementation alone \[[@B68-nutrients-12-01573]\] and another \[[@B70-nutrients-12-01573]\] did not find efficacy using tocotrienol-rich fractions compared to placebo. The only study concerning early-life probiotic supplementation revealed positive effects compared to placebo preventing ADHD onset later in life \[[@B71-nutrients-12-01573]\]. Studies regarding micronutrients mix supplementation found beneficial effects over placebo in general functioning, emotional dysregulation, aggression, and attention \[[@B59-nutrients-12-01573],[@B61-nutrients-12-01573],[@B62-nutrients-12-01573]\]. Importantly, a follow-up work by Rucklidge et al. identified various factors related to response to treatment with micronutrients mix, such as lower pre-treatment folate and B12 levels, being female, greater severity of symptoms and co-occurring disorders in pre-treatment condition, more pregnancy complications, and fewer birth problems \[[@B63-nutrients-12-01573]\]. This work highlighted the role of biological and environmental variables related to response to non-pharmacological treatment. This last area of research needs further research, given the high heterogeneity of results due to confounding biological and environmental variables.

5. Limitations {#sec5-nutrients-12-01573}
==============

There were limitations within the articles described in this review. Results should be interpreted in the light of high heterogeneity related to various methodological factors. Indeed, the included works considered heterogeneous treatments, trial durations, methodologies (e.g., supplementation used as unique or combined treatment), and outcomes, even within the same category of supplements. Hence, it was not possible to carry out a meta-analysis of research results, which instead would be auspicable to provide clinicians with more systematic evidence. Moreover, samples were not uniformly involving only children with ADHD diagnoses; other comorbidities or typically developing children were included in some samples. Studies in this research field are also susceptible of cultural influences such as local dietary habits, thus making results difficult to generalize.

Although the majority of studies used similar parent and/or teacher assessment measures as primary outcomes, in many cases clinicians' evaluation or neurophysiological / neuropsychological assessments were lacking. Only three studies \[[@B38-nutrients-12-01573],[@B59-nutrients-12-01573],[@B65-nutrients-12-01573]\] used neurophysiological data, like magnetic resonance imaging or electroencephalography. These kinds of assessments should be included in future research.

Lastly, the majority of studies found beneficial effects, but this may be due to the fact that only studies that found effects were published. However, a formal evaluation of bias was not conducted due to the non-systematic nature of this review.

6. Conclusions {#sec6-nutrients-12-01573}
==============

This review suggest that supplementation approaches may be effective in add-on to pharmacotherapy in improving some behavioral and neuropsychological indicators in children and adolescents with ADHD. The heterogeneity of results suggests that supplementation should be personalized based on each patient's dietary issues. Several supplementation components that are still poorly investigated and may be effective. Moreover, some nutritional supplementations could represent an alternative treatment or rehabilitation in situations of non-response or poor compliance or lack of tolerability of drug treatments, a field that must still be investigated further.
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nutrients-12-01573-t001_Table 1

###### 

(**a**) Studies comprising supplementation with polyunsaturated fatty acids (PUFAs). (**b**) Studies comprising supplementation with peptides and amino acids derivatives. (**c**) Studies comprising supplementation with a single micronutrient. (**d**) Study comprising supplementation with micronutrients mix. (**e**) Studies comprising supplementation with plant or herbal extracts. (**f**) Study comprising supplementation with probiotics.

  ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **(a)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Authors, Year**                                             **Sample and Age**                                                                                                                                 **Methodology and Durations**                                                                                          **Daily Doses**                                                                                                                                           **Outcome Measures**                                                                                                                                                                                                           **Main Results**

  Anand et al., 2016 \[[@B34-nutrients-12-01573]\]              50 ADHD (35 males),\                                                                                                                               4 months DBRCT\                                                                                                        ATX: 0.5 mg/kg/day.\                                                                                                                                      CPRS-R: parent-rated behavioral indexes.                                                                                                                                                                                       CPRS-R:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          25 subjects taking ATX+ PUFA.\                                                                                         PUFA: EPA 180 mg + DHA 120 mg/day.\                                                                                                                                                                                                                                                                                                                                                      Non significant trend: supplementation group improved in ADHD scores as compared to the control group. Improvement was more evident, although not significant, in males with combined type of ADHD.
                                                                Age range: 4--11 years\                                                                                                                            25 subjects taking ATX.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                (6 ± 2.1 years).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Assareh et al., 2017 \[[@B35-nutrients-12-01573]\]            40 ADHD (30 males),\                                                                                                                               10 weeks DBRCT\                                                                                                        MPH: 0.3 mg/kg/day (in 2 doses).\                                                                                                                         Parent rated ADHD-RS every two weeks.                                                                                                                                                                                          ADHD-RS:\
                                                                ODD was present in 21 subjects.\                                                                                                                   Unspecified subjects taking MPH +DHA + EPA+ Omega 6.\                                                                  Increased to 1 mg/kg/day for 2 weeks.\                                                                                                                                                                                                                                                                                                                                                   Significant time effect: both groups showed an improvement in symptomatology over time.\
                                                                Age range: 6--12\                                                                                                                                  Unspecified subjects taking MPH + Placebo.                                                                             EPA:33 mg/day.\                                                                                                                                                                                                                                                                                                                                                                          
                                                                (PUFA group: 9 ± 2 years; Placebo group 9.2 ± 2 years).\                                                                                                                                                                                                                  DHA: 241 mg/day.\                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                          Omega 6: 180 mg/day.\                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                          Placebo: similar to other capsules.\                                                                                                                                                                                                                                                                                                                                                     

  Barragán et al., 2017 \[[@B36-nutrients-12-01573]\]           90 ADHD (60 males),\                                                                                                                               12 months RPT\                                                                                                         MPH: 0.3 mg/kg/ day, increased to 0.5 mg/kg/day after the first 2 weeks. The dose was increased to 1 mg/kg/day depending on response and tolerability.\   Parent rated ADHD-RS.\                                                                                                                                                                                                         ADHD-RS and CGI-S:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          20 subjects taking MPH.\                                                                                               Omega-3/6: EPA: 558 mg\\day. DHA: 174 mg\\day. GLA: 60 mg\\day.                                                                                           CGI-S: assessment of severity as reported by clinician and parents.                                                                                                                                                            - Significant time x treatment effect: MPH + supplementation group showed greater improvements compared to supplementation alone.\
                                                                Age range: 6--12 years\                                                                                                                            22 subjects taking\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             CGI-S:\
                                                                (8.27 ± 1.74 years).                                                                                                                               Omega-3/6.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     - Slow decrease in Omega-3/6 groups, compared with a rapid decrease and subsequent slight increase in the MPH-containing groups.\
                                                                                                                                                                                                                   27 subjects taking MPH + Omega-3/6.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                            - Adverse events were numerically less frequent with Omega-3/6 or MPH + Omega-3/6 than MPH alone.

  Behdani et al., 2013 \[[@B37-nutrients-12-01573]\]            69 ADHD (55 males), no other neuropsychiatric comorbidities.\                                                                                      Eight weeks DBRCT\                                                                                                     MPH: 2.5--5 mg/day. Increased 2.5--5 mg weekly, to attain a final dose of 1 mg/kg (in two or three doses).\                                               Parent and teacher rated ADHD-RS.                                                                                                                                                                                              ADHD-RS:\
                                                                Age range: 7--15 years\                                                                                                                            36 subjects taking MPH + Omega 3\                                                                                      Omega-3:1000 mg\\2 times a day (240 mg of DHA and 360 mg of EPA).\                                                                                                                                                                                                                                                                                                                       Significant time effect: reduction in both parent's and teacher's rating scores in both groups.
                                                                (8.7 ± 1.7 years).                                                                                                                                 33 subjects taking MPH + Placebo.                                                                                      Placebo: similar to Omega 3 capsules.                                                                                                                                                                                                                                                                                                                                                    

  Bos et al., 2015 \[[@B38-nutrients-12-01573]\]                38 ADHD; 38 TD (76 males), no other neuropsychiatric comorbidities.\                                                                               16 weeks DBRPCT\                                                                                                       Omega 3 fortified margarine: 10 g (650 mg DHA and 650 mg EPA).Placebo: 10 g of similar margarine.                                                         CBCL (parent-rated) SWAN (parent-rated)\                                                                                                                                                                                       CBCL:\
                                                                Age range: 8--14 years (ADHD:10.3± 2.0 years; TD: 10.9 ± 2.0 years).                                                                               19 ADHD^\*^ taking Omega 3.\                                                                                                                                                                                                                                                     fMRI with G/No-Go paradigm                                                                                                                                                                                                     Significant main effect of treatment: supplementation group had less attention problems compared to placebo groups.
                                                                                                                                                                                                                   19 ADHD^\*^ taking Placebo.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                   20 TD taking Omega 3.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                   18 TD taking placebo.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                   \*subjects took MPH before trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Pei-Chen Chang et al., 2019 \[[@B39-nutrients-12-01573]\]     92 ADHD (79 males),\                                                                                                                               12 weeks DBRPCT\                                                                                                       PUFAs (EPA): 1.2 g/day.\                                                                                                                                  CPT: computerized continuous performance test to evaluate attention measures.\                                                                                                                                                 CPT:\
                                                                ODD was present in 51 subjects.\                                                                                                                   48 subjects taking PUFAs.\                                                                                             Placebo: 1.2 g/day soybean oil.                                                                                                                           Parent, teacher and self-rated SNAP IV: checklist of DSM-IV ADHD symptoms.                                                                                                                                                     Significant time x treatment interaction effect: supplementation group showed greater improvement in focused attention compared to placebo group.
                                                                Age range: 6--18 years (9.49 ± 3.05 years).                                                                                                        44 subjects taking Placebo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Cornu et al., 2018 \[[@B40-nutrients-12-01573]\]              162 ADHD (127 males), no other neuropsychiatric comorbidities.\                                                                                    Three months DBRPCT\                                                                                                   Omega 3 for subjects aged 6--8:\                                                                                                                          Parent-rated ADHD-RS-IV: ADHD symptomatology as outlined in the DSM-IV-TR.\                                                                                                                                                    ADHD-RS:\
                                                                Age range 6--15 years (6.9 ± 2.9 years).                                                                                                           77 subjects taking Omega 3.\                                                                                           EPA 336 mg + DHA 84 mg/day.\                                                                                                                              CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      the severity score decreased in both groups. The decrease was significantly higher in the placebo group.\
                                                                                                                                                                                                                   80 subjects taking Placebo.                                                                                            Omega 3 for subjects aged 9--11:\                                                                                                                         "L'Alouette" test: french reading test.\                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                          EPA 504 mg + DHA 126 mg/day.\                                                                                                                             Attentional Performance Tests for\                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                          Omega 3 for subjects aged 12--15:\                                                                                                                        Children.\                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                          EPA 672 mg + DHA 168 mg/day.\                                                                                                                             Children's Depression Inventory: self-rated depression symptomatology.\                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                          Supplementation capsules also contained 100 mg vitamin A + 1.25 mg vitamin D + 3.5 mg vitamin E.\                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                          Placebo: similar to Omega 3.                                                                                                                                                                                                                                                                                                                                                             

  Crippa et al., 2019 \[[@B41-nutrients-12-01573]\]             50 ADHD (46 males), no other neuropsychiatric comorbidities.\                                                                                      Six months DBRPCT\                                                                                                     Omega 3: DHA 500 mg/day.\                                                                                                                                 Parent-rated ADHD-RS version IV: ADHD symptomatology as outlined in the DSM-IV-TR.\                                                                                                                                            A main amelioration effect over time was found in the following measures: ADHD-RS, CPRS-R ADHD index, CPRS-R Global Index restless -- impulsive, CPRS-R Global Index total, DSM-IV hyperactive-- impulsive scale and DSM-IV total, SDQ Hyperactivity scale and on SDQ total difficulties score, CGI severity, C-GAS.\
                                                                Age range: 7--14 years\                                                                                                                            25 subjects taking Omega 3.\                                                                                           Placebo: similar to Omega 3.                                                                                                                              CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      Children in the DHA group showed significantly higher amelioration effect compared to the placebo group in the CHQ. Psychosocial summary and emotional problems on SDQ.
                                                                (Omega 3 group: 11.06 ± 1.85 years; Placebo group: 10.91 ± 1.42 years).                                                                            25 subjects taking Placebo.                                                                                                                                                                                                                                                      SDQ: parent-rated emotional and behavioral indexes.\                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CHQ: parent-rated measure of quality of life.\                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CGI and C-GAS: assessment, severity and improvement of symptoms as reported by clinician.                                                                                                                                      

  Dean et al., 2014 \[[@B42-nutrients-12-01573]\]               16 ADHD, 11 CD (17 males), no other neuropsychiatric comorbidities.\                                                                               Six weeks RPCCT+ Follow-up\                                                                                            Fish oil: 4 g/day, (400 mg EPA + 2000 mg DHA).\                                                                                                           Children's Aggression Scale -- Parent Version.\                                                                                                                                                                                Aggressive behaviour:\
                                                                Age range: 7--14 years\                                                                                                                            12 subjects taking fish oil capsules for six weeks (Phase 1) followed by placebo capsules for six weeks (Phase II).\   Placebo: 4 g\\day (low polyphenol, olive oil and 10 mg standard fish oil to assist in maintaining blinding).                                              MOAS (parent-rated)\                                                                                                                                                                                                           No effect of fish oil treatment was observed on changes in total scores despite it increased serum concentrations of EPA and total omega-3 s.\
                                                                (10.3 ± 2.2 years).                                                                                                                                Nine subjects taking placebo capsules for six weeks (Phase I) followed by fish oil for six weeks (Phase II).                                                                                                                                                                     SDQ (parent-rated)\                                                                                                                                                                                                            SDQ:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Family Assessment Device General Functioning Scale (FAD)\                                                                                                                                                                      Fish oil group worsened in Conduct Subscale but improved in Hyperactivity Subscale.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ADHD-RS (parent-rated)\                                                                                                                                                                                                        No effect of fish oil supplementation was observed for other SDQ subscales or SDQ total score, the ADHD rating scale, or family functioning (FAD).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Cognitive functioning:\                                                                                                                                                                                                        Cognitive measures:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    -Executive control trail-making task.\                                                                                                                                                                                         Fish oil supplementation did not lead to any changes on the stop signal task, trail-making task, or flanker task.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    -Response inhibition--stop signal task\                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Cognitive control:\                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    -Eriksen flanker task.                                                                                                                                                                                                         

  Dubnov-Raz et al., 2014 \[[@B43-nutrients-12-01573]\]         17 drug naïve ADHD (10 males), no other neuropsychiatric comorbidities.\                                                                           Two months DBRPCT\                                                                                                     ALA: 1 g/day.\                                                                                                                                            MOXO-CPT: standardized computerized continuous performance test designed to evaluate ADHD-related symptoms. Four performance indices: attention, timing, impulsivity, and hyperactivity.\                                      No significant between-group difference was found in the changes of the various measures of ADHD symptoms throughout the study period.
                                                                Age range: 6--16 years (ALA group: 11.1 ± 3.00 years; Placebo group: 10.9 ± 2.30 years).                                                           Nine subjects taking Alpha-Linolenic Acid (ALA).\                                                                      Placebo: similar to ALA.                                                                                                                                  CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      
                                                                                                                                                                                                                   Eight subjects taking Placebo.                                                                                                                                                                                                                                                   CTRS-R: teacher-rated behavioral indexes.                                                                                                                                                                                      

  Gustafsson et al., 2010 \[[@B44-nutrients-12-01573]\]         82 ADHD (number of males unspecified), no other neuropsychiatric comorbidities.\                                                                   15 weeks DBRCT\                                                                                                        Omega 3: EPA 500 mg+ DHA 2.7 mg/day.\                                                                                                                     CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      CTRS-inattention / cognitive subscale: children in supplementation group showed significant amelioration effect.\
                                                                Age range: 7--12 years\                                                                                                                            40 subjects taking Omega 3.\                                                                                           Active capsules also contained 10 mg Vitamin E.\                                                                                                          CTRS-R: teacher-rated behavioral indexes.                                                                                                                                                                                      CTRS total score:\
                                                                (no mean age declared).\                                                                                                                           42 subjects taking Placebo.                                                                                            Placebo: similar to Omega 3.                                                                                                                                                                                                                                                                                                                                                             -48% of the children receiving supplementation vs. 9% of placebo improved ≥25%.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   -Among the less hyperactive ⁄ impulsive children, 36% of the ones receiving supplementation vs. 18% receiving placebo\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   improved ≥25%.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   -Among the more hyperactive ⁄ impulsive children, 8 ⁄ 13 receiving supplementation vs. 1 ⁄ 9 receiving placebo improved ≥25%.\

  Hariri et al., 2012 \[[@B45-nutrients-12-01573]\]             103 ADHD (74 males), no other neuropsychiatric comorbidities.\                                                                                     15 week DBRPCT\                                                                                                        Omega 3: EPA 635 mg+ DHA 195 mg/day day.\                                                                                                                 ASQ-P: parent-rated behavioral indexes.                                                                                                                                                                                        ASQ-P: children in EPA + DHA group showed significant improvement.
                                                                Age-range: 6--11.\                                                                                                                                 53 subjects taking Omega 3.\                                                                                           Placebo: similar to Omega 3.                                                                                                                                                                                                                                                                                                                                                             
                                                                (Omega 3 group: 7.90 ± 1.53 years; Placebo group: 7.90 ± 1.45 years).                                                                              50 subjects taking Placebo.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Manor et al., 2012 \[[@B46-nutrients-12-01573]\]              147 ADHD (104 males), no other neuropsychiatric comorbidities.\                                                                                    15 weeks DBRPCT + 15 weeks OL\                                                                                         PS: 300 mg/day.\                                                                                                                                          CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      CPRS-R:\
                                                                Age-range: 6--13 years\                                                                                                                            100 subjects taking Phosphatidylserine (PS) + -Omega 3.\                                                               Omega 3: 120 mg/day (EPA/DHA ratio of 2:1).\                                                                                                              CTRS-R: teacher-rated behavioral indexes.\                                                                                                                                                                                     -Significant reduction in the Global restless/impulsive subscale in supplementation group\
                                                                (Supplementation group: 9.2 ± 2.0 years;\                                                                                                          47 subjects taking Placebo.                                                                                            Placebo: similar to supplementation.\                                                                                                                     SDQ: parent-rated emotional and behavioral indexes.\                                                                                                                                                                           -Children with more severe symptomatology revealed a significant reduction in the ADHD-Index and hyperactive components.\
                                                                Placebo group: 9.2 ± 1.8 years).                                                                                                                                                                                                                                                                                                                                                                                                    CHQ: parent-rated measure of quality of life.                                                                                                                                                                                  CPRS-R and CTRS-R:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Children that switched to supplementation group from placebo showed a significant reduction in subscales severity scores compared to baseline.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   CHQ: significant improvement in Parent impact-emotional (PE) subscale in supplementation group.

  Matsudaira et al., 2015 \[[@B47-nutrients-12-01573]\]         76 ADHD (76 males), no other neuropsychiatric comorbidities.\                                                                                      Three months DBRPCT\                                                                                                   LC-PUFA:\                                                                                                                                                 CTRS-R: teacher-rated behavioral indexes (specifically, the authors considered the ADHD index).                                                                                                                                No between-group difference was found in the changes of the various measures of ADHD symptoms throughout the study period.
                                                                Age-range: 12--16 years (LC-PUFA group: 13.7 ± 1.2 years;\                                                                                         38 subjects taking LC-PUFA\                                                                                            EPA 558 mg + DHA 174 mg + CLA 60 mg + vitamin E 9.6 mg/day.\                                                                                                                                                                                                                                                                                                                             
                                                                Placebo group: 13.7 ± 1.1 years).                                                                                                                  38 subjects taking Placebo.                                                                                            Placebo: similar to LC-PUFA.                                                                                                                                                                                                                                                                                                                                                             

  Milte et al., 2012 \[[@B48-nutrients-12-01573]\]              87 ADHD or parent-rated symptoms higher than the 90th percentile on the CPRS-R (67 males), including parent-reported learning difficulties.\       Four months RCT\                                                                                                       EPA-rich oil:\                                                                                                                                            WIAT-III word reading and spelling subtests: literacy assessment.\                                                                                                                                                             No between-group or within-group difference was found in the changes of the various measures of symptoms throughout the study period.\
                                                                Age range: 6--13 years\                                                                                                                            30 subjects taking EPA-rich oil.\                                                                                      EPA 1109 mg+ DHA 108 mg/day.\                                                                                                                             WISC-III vocabulary subtest: literacy assessment.\                                                                                                                                                                             In a subgroup of 17 children with learning difficulties an increased erythrocyte DHA was more strongly associated with improved word reading (*r* = 0.683), improved spelling (*r* = 0.556), an improved ability to divide attention (*r* = 0.676), and lower parent ratings of oppositional behavior (*r* = 0.777), hyperactivity (*r* = 0.702), restlessness (*r* = 0.705), and overall ADHD symptoms (*r* = 0.665).
                                                                (EPA-rich group: 8.77 ± 1.76 years;\                                                                                                               28 subjects taking DHA-rich oil.\                                                                                      DHA-rich oil:\                                                                                                                                            CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      
                                                                DHA-rich group: 8.89 ± 1.60 years;\                                                                                                                29 subjects taking LA oil.                                                                                             DHA 1032 mg +\                                                                                                                                            Abbreviated test of everyday attention for children: attention assessment.\                                                                                                                                                    
                                                                LA-rich group:\                                                                                                                                                                                                                                                           EPA 264 mg/day.\                                                                                                                                          Computerized go/no-go task: inhibition assessment.                                                                                                                                                                             
                                                                9.14 ± 2.03 years).                                                                                                                                                                                                                                                       LA oil: 1467 mg/day.\                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                          Each capsule also contained low concentration of vitamin E.                                                                                                                                                                                                                                                                                                                              

  Milte et al., 2015 \[[@B49-nutrients-12-01573]\]              87 ADHD or parent-rated symptoms higher than the 90th percentile on the CPRS-R (67 males), including parent-reported learning difficulties.\       12 months Three-way, crossover clinical trial\                                                                         EPA-rich oil:\                                                                                                                                            WIAT-III word reading and spelling subtests: literacy assessment.\                                                                                                                                                             No between-group or within-group difference was found in the changes of the various measures of symptoms throughout the study period.\
                                                                Age range: 6--13 years (8.91 ± 1.73 years).                                                                                                        Group 1: EPA→DHA→LA\                                                                                                   EPA 1109 mg+ DHA 108 mg/day.\                                                                                                                             WISC-III vocabulary subtest: literacy assessment.\                                                                                                                                                                             An increased proportion of erythrocyte EPA + DHA was associated with improved spelling (*r* = 0.365) and attention (*r* = −0.540) and reduced oppositional behavior (*r* = −0.301), hyperactivity (*r* = −0.310), cognitive problems (*r* = −0.326), DSM-IV hyperactivity (*r* = −0.270) and DSM-IV inattention (*r* = −0.343).
                                                                                                                                                                                                                   Group 2:\                                                                                                              DHA-rich oil:\                                                                                                                                            CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      
                                                                                                                                                                                                                   DHA→LA→EPA\                                                                                                            DHA 1032 mg + EPA 264 mg/day.\                                                                                                                            Abbreviated Test of Everyday Attention for Children: attention assessment.\                                                                                                                                                    
                                                                                                                                                                                                                   Group 3:\                                                                                                              LA oil: 1467 mg/day.\                                                                                                                                     Computerized go/no-go task: inhibition assessment.                                                                                                                                                                             
                                                                                                                                                                                                                   LA→EPA→DHA                                                                                                             Each capsule also contained low concentration of vitamin E.\                                                                                                                                                                                                                                                                                                                             

  Mohammadzadeh et al., 2019 \[[@B50-nutrients-12-01573]\]      60 ADHD (49 males), no other neuropsychiatric comorbidities.\                                                                                      Eight weeks DBRCT\                                                                                                     Omega 3: EPA 180 mg + DHA 120 mg/day (from second week 2 times a day).\                                                                                   ADHD-RS-IV parent rated                                                                                                                                                                                                        No significant effect was found.
                                                                Age range: 6--12 years\                                                                                                                            31 subjects taking MPH + PUFA.\                                                                                        Placebo: similar to Omega 3.\                                                                                                                                                                                                                                                                                                                                                            
                                                                (PUFA group: 8.20 ± 1.72 years;\                                                                                                                   29 subjects taking MPH + Placebo.                                                                                      MPH: 10 mg/day (in 2 doses); 20--30 mg/kg/day (in 2 doses) from second week.                                                                                                                                                                                                                                                                                                             
                                                                Placebo Group:7.7 ± 1.65 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Perera et al., 2012 \[[@B51-nutrients-12-01573]\]             94 ADHD (69 males), including ODD, CD, SLD and tics comorbidities.\                                                                                Six months DBRPCT\                                                                                                     Omega capsules: Omega 3 296.37 mg+ Omega 6 180.75 mg (ratio 1.6:1).\                                                                                      Parent-rated checklist assessing the following domains: aggressiveness, restlessness, inattention, distractibility, easy anger, impulsiveness, fighting, cooperation, completing work, wait for turn, academic performance.\   Significant reduction in severity score in treatment group compared to placebo in the following measures: aggressiveness, restlessness, completing work, and academic performance, inattention, impulsiveness, and cooperation with parents and teachers.
                                                                Age range: 6--12 years\                                                                                                                            48 subjects \* taking Omega 3/6.\                                                                                      Placebo: similar to Omega 3/6.\                                                                                                                           Total score range: 11--33.                                                                                                                                                                                                     
                                                                (Omega 3 group: 9.4 ± 1.5 years; Placebo group: 9.2 ± 1.5 years).                                                                                  46 subjects\* taking Placebo.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                   \*subjects took MPH before trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Rodríguez et al., 2020 \[[@B52-nutrients-12-01573]\]          66 ADHD (47 males),\                                                                                                                               Six months DBRPCT\                                                                                                     PUFA sachet: DHA 1000 mg+ EPA 90 mg+ DPA 150 mg + vitamin E 4.5 mg+ carbohydrates 0.94 g (1 sachet/day in subjects ≤32 kg; 2\                             CPRS: parent-rated behavioral indexes.\                                                                                                                                                                                        CPRS:\
                                                                including SLD, Anxiety, Tourette's syndrome, psychomotor/behavioral problems comorbidities.\                                                       32 subjects \* taking PUFA\                                                                                            sachets/day in subjects \>32 kg).\                                                                                                                        EDAH scale: parent-rated behavioral indexes.\                                                                                                                                                                                  Significant within-group time effect: supplementation group showed improvement in behavioral variables; placebo group showed a behavioral symptomatology worsening.\
                                                                Age range: 6--18 years\                                                                                                                            34 subjects \* taking Placebo\                                                                                         Placebo: similar to PUFA sachet.                                                                                                                          AULA Nesplora virtual test: test of attentional processes, impulsivity and motor activity.\                                                                                                                                    EDAH scale:\
                                                                (11.7 ± 3.1 years).                                                                                                                                \* psychostimulant medication was allowed                                                                                                                                                                                                                                        D2-test: paper and pencil test for selective and sustained attention.                                                                                                                                                          Significant time x treatment interaction effect: supplementation group in post -- treatment condition showed better behavioral indexes compared to placebo group.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   AULA Nesplora virtual test:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Non-significant trend of higher amelioration in supplementation group.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   d-2 test:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   significant within-group time effect: both study groups showed improvements in cognitive variables.

  Widenhorn-Müller et al., 2014 \[[@B53-nutrients-12-01573]\]   95 ADHD (74 males), no other neuropsychiatric comorbidities.\                                                                                      Four months DBRPCT\                                                                                                    Omega 3: EPA 600 mg + DHA 120 mg/day.\                                                                                                                    HAWIK-IV: General cognitive ability, working memory, speed of information processing.\                                                                                                                                         HAWIK-IV:\
                                                                Age range: 6--12 years (Omega 3 group: 8.90 ± 1.48 years; Placebo group: 8.92 ± 1.24 years).                                                       46 subjects taking Omega 3.\                                                                                           Active capsules also contained 15 mg Vitamin E.\                                                                                                          DIS-YPS-II: parent-and teacher-rated questionnaires corresponding to the ICD-10 and DSM-IV\                                                                                                                                    significant time x treatment interaction: supplementation group showed an improvement in working memory function compared to placebo -- taking group.\
                                                                                                                                                                                                                   49 subjects taking Placebo.                                                                                            Placebo: similar to Omega 3.                                                                                                                              diagnostic criteria for ADHD.\                                                                                                                                                                                                 Improved working memory correlated with increased erythrocyte EPA and DHA and decreased AA.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CBCL: parent-rated questionnaire addressing behavioral and emotional problems.\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    TRF: teacher-rated questionnaire addressing behavioral and emotional problems and academic performance.\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    KITAP and TAP: computerized test batteries as measures for attentional performance.                                                                                                                                            

  **(b)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Authors, Year**                                             **Sample and Age**                                                                                                                                 **Methodology and Durations**                                                                                          **Daily Doses**                                                                                                                                           **Outcome Measures**                                                                                                                                                                                                           **Main Results**

  Abbasi et al., 2011 \[[@B15-nutrients-12-01573]\]             40 ADHD (28 males),\                                                                                                                               Six weeks DBRPCT\                                                                                                      MPH week 1: 10 mg/day.\                                                                                                                                   Teacher and Parent rated ADHD-RS-IV.                                                                                                                                                                                           Teacher and Parent rated ADHD-RS-IV: no significant between-groups outcome results.\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          19 subjects taking MPH + Acetyl-L-carnitine (ALC).\                                                                    MPH week 2: 20 mg/day.\                                                                                                                                                                                                                                                                                                                                                                  However, those in the ALC group experienced fewer adverse events than the placebo group regarding headaches and irritability.
                                                                Age range: 7--13 years\                                                                                                                            19 subjects taking MPH + Placebo.                                                                                      MPH week 3: 30 mg/day.\                                                                                                                                                                                                                                                                                                                                                                  
                                                                (ALC group:8.84 ± 2.03 years; Placebo group: 8.36 ± 1.53 years).                                                                                                                                                                                                          ALC: 500--1500 mg/kg/day.\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                          Placebo + MPH: 20--30 mg/day/Kg.                                                                                                                                                                                                                                                                                                                                                         

  Ghajar et al., 2018 \[[@B17-nutrients-12-01573]\]             50 ADHD (40 males), not excluding ODD.\                                                                                                            Eight weeks DBRPCT\                                                                                                    MPH: 0.5--1.5 mg/kg/day.\                                                                                                                                 Primary outcome: Parent rated ADHD-RS-IV.\                                                                                                                                                                                     Primary outcome: Parent rated ADHD-RS-IV. Significant time x treatment interaction effect both at weeks 4 and 8: MPH + supplementation group showed greater improvements compared to MPH + placebo group.\
                                                                Age range: 6--17 years (l-carnosine group: 9.12 ± 2.18 years; Placebo group: 8.28 ± 1.59 years).                                                   25 subjects taking MPH + l-carnosine.\                                                                                 Week 1:10 mg/day.\                                                                                                                                        Secondary outcome: Teacher rated ADHD-RS-IV.\                                                                                                                                                                                  Secondary outcome: Teacher rated ADHD-RS-IV. No significant time x treatment interaction effect.
                                                                                                                                                                                                                   25 subjects taking\                                                                                                    Week 2-end: 20 mg/day.\                                                                                                                                   Both rated at baseline and at weeks four and eight.                                                                                                                                                                            
                                                                                                                                                                                                                   MPH + Placebo.                                                                                                         Subjects \>30 kg: 30 mg/day.\                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                          l-carnosine: 800 mg/day.\                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                          Placebo: 800 mg/day.                                                                                                                                                                                                                                                                                                                                                                     

  Hirayama et al., 2013 \[[@B21-nutrients-12-01573]\]           36 ADHD (34 males),\                                                                                                                               Eight weeks DBRPCT\                                                                                                    PS: 100 mg/day.\                                                                                                                                          ADHD diagnostic criteria of DSM-IV-TR.\                                                                                                                                                                                        Significant treatment effect: supplementation group showed post-treatment improvements compared to pre-treatment condition in ADHD, AD and HD symptoms (DSM-IV-TR), short-term auditory memory (WISC-III) and total number of errors in the reverse differentiation test (inattention -- impulsivity), as well as total inattention errors and total errors over time (Go/No-Go).\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          19 subjects taking Phosphatidylserine (PS).\                                                                           Placebo: 100 mg/day.                                                                                                                                      WISC-III (Digit Span Test).\                                                                                                                                                                                                   No significant differences were observed in other measurements and in the placebo group.
                                                                Age range: 4--14 years\                                                                                                                            17 subjects taking Placebo.                                                                                                                                                                                                                                                      go/no-go experiment.                                                                                                                                                                                                           
                                                                (Phosphatidylserine group: 9.1 ± 1.7 years; Placebo: 8.7 ± 3.0 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  **(c)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Authors, Year**                                             **Sample and Age**                                                                                                                                 **Methodology and Durations**                                                                                          **Daily Doses**                                                                                                                                           **Outcome Measures**                                                                                                                                                                                                           **Main Results**

  Arnold et al., 2011 \[[@B54-nutrients-12-01573]\]             52 ADHD (43 males),\                                                                                                                               13 weeks (8 + 5) DBRPCT + 8 weeks OL\                                                                                  Zinc glycinate group 1: 15 mg/day (20 subjects).\                                                                                                         Parent and Teacher rated SNAP IV: checklist of DSM-IV ADHD symptoms.\                                                                                                                                                          Phase 1:\
                                                                ODD, CD comorbidities.\                                                                                                                            Phase 1\                                                                                                               Zinc glycinate group 2: 15 mg/2 times day (8 subjects).\                                                                                                  CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      Parent and teacher rating showed no consistent tendency of superiority of zinc over placebo. Neuropsychological cognitive motor results are inconsistent, although a bit more favorable to zinc.\
                                                                Age range: 6--14 years\                                                                                                                            28 subjects taking Zinc glycinate (group 1 and 2).\                                                                    AMPH: 25 kg: 5 mg/day; 25--45 kg: 10 mg/day; \>45 kg: 15 mg/day.\                                                                                         Short-term recognition memory task.\                                                                                                                                                                                           *Phase 2/3:*\
                                                                (Zinc group 1: 9.61 ± 3.36 years;\                                                                                                                 24 subjects taking Placebo.\                                                                                           Placebo: similar to Zinc glycinate.                                                                                                                       Continuous performance task 11.\                                                                                                                                                                                               Optimal mg/kg AMPH dose with in zinc group 2 was 37% lower than with placebo.
                                                                Zinc group 2: 8.89 ± 2.31 years;\                                                                                                                  Phase 2/3\                                                                                                                                                                                                                                                                       Seat activity using a ''wiggle'' seat.\                                                                                                                                                                                        
                                                                Placebo group: 10.24 ± 2.69 years).                                                                                                                28 subjects taking Zinc glycinate + d-amphetamine.\                                                                                                                                                                                                                              CGI-S and CGI-I: assessment of severity and improvement as reported by clinician.\                                                                                                                                             
                                                                                                                                                                                                                   24 subjects taking Placebo + d-amphetamine.                                                                                                                                                                                                                                      Parent and child children's depression inventory.                                                                                                                                                                              

  Noorazar et al., 2020 \[[@B55-nutrients-12-01573]\]           60 ADHD (48 males),\                                                                                                                               Six weeks DBRPCT\                                                                                                      MPH: 0.5--1 mg/kg/day.\                                                                                                                                   CPRS-R: parent-rated behavioral indexes.                                                                                                                                                                                       CPRS-R.\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          30 subjects taking MPH+ Zinc sulfate syrup.\                                                                           Zinc sulfate syrup: 10 mg/day\                                                                                                                                                                                                                                                                                                                                                           Significant time x treatment interaction effect: MPH + supplementation group showed greater improvements compared to MPH + placebo group in inattention score.
                                                                Age range: 7--12 years\                                                                                                                            30 subjects taking MPH + Placebo.                                                                                      Placebo: 10 mg/day.                                                                                                                                                                                                                                                                                                                                                                      
                                                                (Control group: 9.30 ± 1.38 years; Zinc group: 8.87 ± 1.97 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Salehi et al., 2016 \[[@B56-nutrients-12-01573]\]             150 ADHD (111 males),\                                                                                                                             Eight weeks DBRCT\                                                                                                     MPH: 0 mg/day for subjects \<20 kg; 10 mg/2 times a day \> 20 kg.\                                                                                        CPRS-R (parent-rated behavioral indexes) and CTRS-R (teacher-rated behavioral indexes) every 2 weeks.                                                                                                                          CPRS-R and CTRS-R:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          50 subjects taking MPH+ Placebo.\                                                                                      Omega 3: 100 mg EPA for subjects \<25 kg; 200 mg for subjects 26--35 kg;400 mg for subjects \>35 kg/day.\                                                                                                                                                                                                                                                                                Significant time x treatment interaction effects in children with attention deficit disorder subtype:\
                                                                Age range: 6--15 years\                                                                                                                            50 subjects taking MPH+ Omega 3.\                                                                                      Zinc sulfate: 22 mg/day.                                                                                                                                                                                                                                                                                                                                                                 - zinc group showed greater improvements compared to placebo group;\
                                                                (Control group: 9.12 ± 2.2 years;\                                                                                                                 50 subjects taking MPH+ Zinc sulfate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           - Omega 3 group showed greater improvements compared to the zinc group.
                                                                Omega 3 group: 8.6 ± 1.7 years;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                Zinc group: 9.5 ± 2.5 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Dehbokri et al., 2019 \[[@B57-nutrients-12-01573]\]           96 ADHD (80 males),\                                                                                                                               Six weeks DBRCT\                                                                                                       MPH: unspecified.\                                                                                                                                        CPRS-R: parent-rated behavioral indexes.                                                                                                                                                                                       CPRS-R:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          51 subjects taking MPH + Vitamin D.\                                                                                   Vitamin D3: 50,000 IU/week.\                                                                                                                                                                                                                                                                                                                                                             Significant time x treatment interaction effect: supplementation group showed a significant decrease in hyperactivity, impulsivity and attention problems compared to placebo group.\
                                                                Age range: 2--18 years\                                                                                                                            45 subjects taking MPH + Placebo.                                                                                      Placebo: similar to Vitamin D3.                                                                                                                                                                                                                                                                                                                                                          These results improved considerably in patients with insufficient levels of Vitamin D at baseline.
                                                                (Vitamin D group: 9.76 ± 2.38 years; Placebo group: 8.58 ± 2.02 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Elshorbagy et al., 2018 \[[@B58-nutrients-12-01573]\]         35 ADHD with vitamin D deficiency,\                                                                                                                12 weeks Case-Control Prospective Interventional Study\                                                                MPH: 0.3--1 mg/kg/3 times a day.\                                                                                                                         CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      CPRS-R:\
                                                                including ODD, SLD comorbidities (number of males unspecified).\                                                                                   16 subjects taking MPH + Vitamin D.\                                                                                   Vitamin D3: 3000 IU/day.\                                                                                                                                 Weekly Parent Ratings Behaviour.                                                                                                                                                                                               Significant time x treatment interaction effect: ADHD who received vitamin D showed a significant improvement in conceptual level, inattention, opposition, hyperactivity and impulsivity compared with placebo group.
                                                                Age range: 7--14 years\                                                                                                                            19 subjects taking MPH + Placebo.                                                                                      Placebo: similar to Vitamin D3.                                                                                                                                                                                                                                                                                                                                                          
                                                                (9.3 ± 2.6 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Mohammadpour et al., 2018 \[[@B25-nutrients-12-01573]\]       62 ADHD (46 males),\                                                                                                                               Eight weeks DBRPCT\                                                                                                    MPH: 0.3--1 mg/kg/3 times a day.\                                                                                                                         WPREMB: parent-rated morning and evening behavioural indexes.\                                                                                                                                                                 WPREMB:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          25 subjects taking MPH + Vitamin D.\                                                                                   Vitamin D tablets: 2000 IU/day.\                                                                                                                          Parent rated ADHD-RS-IV.\                                                                                                                                                                                                      Significant time x treatment interaction effect: ADHD who received vitamin D showed a significant improvement in total score and evening symptoms compared to placebo group.\
                                                                Age range: 5--12 years\                                                                                                                            29 subjects taking MPH + Placebo.                                                                                      Placebo: similar to Vitamin D.                                                                                                                            CPRS-R: parent-rated behavioral indexes.                                                                                                                                                                                       ADHD-RS:\
                                                                (Vitamin D group: 7.70 ± 1.77 years; Placebo group: 8.03 ± 1.44 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Significant within-group time effect: ADHD who received vitamin D showed an improvement in total score.\

  **(d)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Authors, year**                                             **Sample and age**                                                                                                                                 **Methodology and durations**                                                                                          **Daily doses**                                                                                                                                           **Outcome measures**                                                                                                                                                                                                           **Main results**

  Borlase et al., 2019 \[[@B59-nutrients-12-01573]\]            27 ADHD drug naïve (27 males), excluding only ASD and epilepsy comorbidities.\                                                                     10 weeks DBRPCT\                                                                                                       Micronutrients (comprising 13 vitamins, 17 minerals, 4 amino acids): titration over a week up to 12 capsules/day (in 3 doses).\                           CGI-I: assessment of improvement as reported by clinician.\                                                                                                                                                                    Questionnaires:\
                                                                Age range: 7--12\                                                                                                                                  13 subjects taking Micronutrients (DEN Formula).\                                                                      If there was no clinical response after four weeks, subjects could choose to take 15 pills/day.\                                                          Clinician-rated ADHD-RS-IV.\                                                                                                                                                                                                   Significant advantage of supplementation group over placebo for general functioning, emotional dysregulation, aggression and inattention.\
                                                                (Micronutrients group: 10.75 ± 1.50 years; Placebo group: 10.17 ± 1.36 years).                                                                     14 subjects taking Placebo.                                                                                            Placebo: similar to micronutrients.                                                                                                                       CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      MRI:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    CTRS-R: teacher-rated behavioral indexes.\                                                                                                                                                                                     No significant between-groups differences.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Magnetic Resonance Imaging (MRI)                                                                                                                                                                                               In the treatment group there was a non-significant trend for:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   - decreased choline in the striatum;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   - decreased glutamate in the prefrontal cortex;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   - increased grey matter in the anterior thalamus;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   - increased white matter in the fornix;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   - improved network integrity of the default mode network, dorsal attention network and frontal executive network.

  Hemamy et al., 2020 \[[@B60-nutrients-12-01573]\]             66 ADHD (46 males),\                                                                                                                               Eight weeks DBRCT\                                                                                                     MPH: unspecified.\                                                                                                                                        CPRS-R: parent-rated behavioral indexes.                                                                                                                                                                                       CPRS-R:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          33 subjects taking MPH + Vitamin D + Magnesium.\                                                                       Vitamin D: 50,000 IU/week.\                                                                                                                                                                                                                                                                                                                                                              Significant time x treatment interaction effect: ADHD who received supplementation showed a significant improvement in conduct problem score, social problem and anxiety score compared to placebo group.\
                                                                Age range: 6--12 years\                                                                                                                            33 subjects taking MPH + Placebos.                                                                                     Mg: 6 mg/kg/day.\                                                                                                                                                                                                                                                                                                                                                                        
                                                                (Vitamin D group: 9.06 ± 1.76 years;\                                                                                                                                                                                                                                     Placebo: similar to Vitamin D or Mg.                                                                                                                                                                                                                                                                                                                                                     
                                                                Placebos group: 9.15 ± 1.46 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Rucklidge et al., 2018 \[[@B61-nutrients-12-01573]\]          93 ADHD (69 males),\                                                                                                                               10 weeks FBRPCT\                                                                                                       Micronutrients: 3--12/15 capsule/day divided into 3 doses (it contains 13 vitamins, 17 minerals, 4 amino acids).\                                         CGI-I and C-GAS: assessment of severity and improvement as reported by clinician.\                                                                                                                                             CGI-I: the number of responders in supplementation group was 20 (51%) versus 11 (27%) on placebo.\
                                                                excluding only ASD and epilepsy comorbidities.\                                                                                                    47 subjects taking Micronutrients.\                                                                                    Placebo: similar to micronutrients.\                                                                                                                      Clinician-rated ADHD-RS-IV.\                                                                                                                                                                                                   Clinician-rated ADHD-RS-IV.\
                                                                Age range: 7--12 years\                                                                                                                            46 subjects taking Placebo.                                                                                                                                                                                                                                                      CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      Improvement in inattention and hyperactivity symptoms, aggression, emotional dysregulation, conduct problem and problem behaviour in ADHD who received supplementation compared with placebo group.\
                                                                (Micronutrients group: 10.06 ± 1.56 years; Placebo group: 9.43 ± 1.53 years).                                                                                                                                                                                                                                                                                                                                                       CTRS-R: teacher-rated behavioral indexes.\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    SDQ: parent- and teacher-rated emotional and behavioral indexes.\                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    BRIEF: teacher-rated behavioural measures of executive skills in everyday environment.                                                                                                                                         

  Darling et al., 2019 \[[@B62-nutrients-12-01573]\]            84 ADHD no drug naïve (62 males). See Rucklidge 2018.\                                                                                             Naturalistic Follow-up Study after 12 month post-baseline\                                                             Micronutrients: 8--15 capsule/day (it contains 13 vitamins, 17 minerals, 4 amino acids).                                                                  CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      More of those who stayed on supplementation (84%) were identified as ''Much'' or ''Very Much'' improved overall relative to baseline functioning, compared to 50% of those who switched to psychiatric medications and 21% of those who discontinued treatment.\
                                                                43 subjects from Micronutrients group;\                                                                                                            19 subjects stayed on trial micronutrients.\                                                                                                                                                                                                                                     SDQ: parent-rated emotional and behavioral indexes.\                                                                                                                                                                           79% of those still taking micronutrients, 42% of those using medications, and 23% of those who discontinued treatment were considered remitters based on parent-reported ADHD.
                                                                41 subjects from Placebo group.                                                                                                                    21 subjects switched to medications.\                                                                                                                                                                                                                                            Parent-rated CMRS for a measure of emotion dysregulation.\                                                                                                                                                                     
                                                                                                                                                                                                                   35 subjects stopped all treatments.\                                                                                                                                                                                                                                             Parent-rated SCARED-R for a measure of anxiety symptoms.\                                                                                                                                                                      
                                                                                                                                                                                                                   Nine subjects mixed micronutrients and medications.\                                                                                                                                                                                                                             Eating Behaviour Questionnaire.\                                                                                                                                                                                               
                                                                                                                                                                                                                   27/84 subjects added psychological/ other intervention.                                                                                                                                                                                                                          Acceptability of Treatment questionnaire.                                                                                                                                                                                      

  Rucklidge et al., 2019 \[[@B63-nutrients-12-01573]\]          71 ADHD (55 males). See Rucklidge 2018.\                                                                                                           Data from Rucklidge (2018) +10 weeks OL\                                                                               Micronutrients: 3--12/15 capsule/day divided into 3 doses (it contains 13 vitamins, 17 minerals, 4 amino acids).\                                         Clinician-rated ADHD-RS-IV.\                                                                                                                                                                                                   Varying predictors were found across outcomes: lower pre-treatment folate and B12 levels, being female, greater severity of symptoms and co-occurring disorders in pre-treatment condition, more pregnancy complications and fewer birth problems were identified as possible predictors of greater improvement for outcome measures.\
                                                                Age range: 7--12\                                                                                                                                  40 subjects from RCT phase (taking micronutrients).\                                                                   No Placebo.                                                                                                                                               CGI-I and C-GAS: assessment of severity and improvement as reported by clinician.\                                                                                                                                             
                                                                (9.7 ± 1.5 years).                                                                                                                                 31 subjects from OL phase (taking micronutrients).                                                                                                                                                                                                                               CPRS-R: parent-rated behavioral indexes.\                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Parent-rated CMRS for a measure of emotion dysregulation.\                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    SDQ: parent-rated emotional and behavioral indexes.                                                                                                                                                                            

  **(e)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Authors, year**                                             **Sample and age**                                                                                                                                 **Methodology and durations**                                                                                          **Daily doses**                                                                                                                                           **Outcome measures**                                                                                                                                                                                                           **Main results**

  Katz et al., 2010\                                            92 ADHD (92 males),\                                                                                                                               Four months DBRPCT\                                                                                                    CHP: 3 mL\                                                                                                                                                TOVA task to measure attention\                                                                                                                                                                                                TOVA task:\
  \[[@B64-nutrients-12-01573]\]                                 no other neuropsychiatric comorbidities.\                                                                                                          73 subjects taking Compound Herbal Preparation (CHP).\                                                                 three times daily, before\                                                                                                                                Daily side effect questionnaire                                                                                                                                                                                                Significant within-group time effect: supplementation group showed significant improvement in the 4 subscales and overall scores, compared with no improvement in the control group.\
                                                                Age range: 6--12 years\                                                                                                                            19 subjects taking Placebo.                                                                                            meals, diluted in 50 to 60 mL of water.\                                                                                                                                                                                                                                                                                                                                                 No serious side effects were reported.
                                                                (CHP group:9.82± 1.56 years; Placebo group: 9.36 ± 1.97 years).                                                                                                                                                                                                           Placebo: similar to CHP.                                                                                                                                                                                                                                                                                                                                                                 

  Ko et al., 2014\                                              70 ADHD/ADHD NOS (44 males),\                                                                                                                      Eight weeks DBRPCT\                                                                                                    KRG: 1g (extract/pouch) twice a day.\                                                                                                                     Primary outcome:\                                                                                                                                                                                                              Primary outcome:\
  \[[@B65-nutrients-12-01573]\]                                 no other neuropsychiatric comorbidities.\                                                                                                          33 subjects taking Korean Red Ginseng (KRG).\                                                                          Placebo dose: one pouch twice a day.                                                                                                                      DSM-IV criteria for inattention and hyperactivity scale scores.\                                                                                                                                                               Active treatment significantly improved the inattention scores and hyperactivity scores.\
                                                                Age range: 6--15\                                                                                                                                  37 subjects taking Placebo.                                                                                                                                                                                                                                                      Secondary outcomes:\                                                                                                                                                                                                           Secondary outcomes:\
                                                                (KRG group = 10.94 ± 2.26 years; Placebo group = 10.86 ± 2.41 years).                                                                                                                                                                                                                                                                                                                                                               QEEG TBR: EEG theta/beta ratio.\                                                                                                                                                                                               - Supplementation group showed a significantly decrease in QEEG TBR.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Salivary cortisol.\                                                                                                                                                                                                            - No significant effect of supplementation on cortisol and DHEA levels.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    DHEA levels.                                                                                                                                                                                                                   - No serious adverse reactions to KRG.

  Li et al., 2011 \[[@B66-nutrients-12-01573]\]                 72 ADHD (47 males), no other neuropsychiatric comorbidities.\                                                                                      Eight weeks DBRCT\                                                                                                     MPH: 1 mg/kg/day.\                                                                                                                                        Teacher and Parent ADHD-RS to measure behavior.\                                                                                                                                                                               Teacher and parent ADHD-RS:\
                                                                Age range: 6--13 years\                                                                                                                            36 subjects taking MPH.\                                                                                               NDG: 5 mg/kg/day.                                                                                                                                         Blood levels of dopamine (DA) and homovanillic acid (HVA)\                                                                                                                                                                     Scores were reduced from baseline to week 8 in both groups, but there were no significant differences between NDG and MPH groups.\
                                                                (NDG group: 9.3 ± 1.8 years;\                                                                                                                      36 subjects taking Ningdong granule (NDG).\                                                                                                                                                                                                                                      Side effect questionnaire                                                                                                                                                                                                      MPH group had more side effects than NDG group (significant effect only in hypersomnia).\
                                                                MPH group: 9.2 ± 2.2 years).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       DA levels showed no significant change during the study.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   HVA in supplementation group was higher at the end of the research, but there was no significant difference between two groups. HVA increasing was associated with improved scores of Teacher and Parent ADHD-RS.

  Motaharifard et al., 2019\                                    50 ADHD (33 males), no other neuropsychiatric comorbidities.\                                                                                      Eight weeks TBRCT\                                                                                                     MPH:\                                                                                                                                                     Teacher and Parent ADHD-RS to measure behavior, every 2 weeks.\                                                                                                                                                                Teacher and Parent ADHD-RS:\
  \[[@B67-nutrients-12-01573]\]                                 Age range: 6--14 years\                                                                                                                            25 subjects taking MPH+ Placebo syrup.\                                                                                week 1--5 mg tablet twice daily;\                                                                                                                         Side effects checklist.                                                                                                                                                                                                        No significant differences were observed between the two groups.\
                                                                (MPH group: 7.5 ± 1.5 years;\                                                                                                                      25 subjects taking Placebo tablet + Sweet almond syrup.                                                                from week 2--10 mg tablet twice daily;\                                                                                                                                                                                                                                                                                                                                                  Both groups exhibited a similar declining linear trend in ADHD symptoms over time.\
                                                                Sweet almond group: 6.6 ± 1.0 years).                                                                                                                                                                                                                                     subjects \>30 kg received a 10 mg tablet thrice daily from the third week.\                                                                                                                                                                                                                                                                                                              Sweet almond syrup had less side effects (only increased appetite).
                                                                                                                                                                                                                                                                                                                                          Placebo syrup: 5 cc/3 times a day.\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                          Sweet almond syrup: 5 cc/3 times a day.\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                          Placebo tablet: 5 mg twice daily.                                                                                                                                                                                                                                                                                                                                                        

  Salehi et al., 2010 \[[@B68-nutrients-12-01573]\]             50 ADHD (39 males),\                                                                                                                               Six weeks DBRCT\                                                                                                       G. biloba: 80--120 mg/day/kg (80 mg/day for \<30 kg and 120 mg/day for \>30 kg).\                                                                         Primary outcomes:\                                                                                                                                                                                                             Parent and Teacher ADHD-RS:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          25 subjects taking Ginkgo biloba.\                                                                                     MPH: 20--30 mg/day/kg (20 mg/day for \<30 kg and 30 mg/day for \>30 kg).                                                                                  Parent and Teacher ADHD-RS to measure behavior.\                                                                                                                                                                               Supplementation was less effective than MPH.\
                                                                Age range: 6--14 years\                                                                                                                            25 subjects taking MPH.                                                                                                                                                                                                                                                          Secondary outcomes:\                                                                                                                                                                                                           The difference between supplementation and MPH groups in the frequency of side effects was not significant, except for more frequent decreased appetite, headache and insomnia in the MPH group.
                                                                (G. biloba group: 9.12 ± 1.61 years;\                                                                                                                                                                                                                                                                                                                                                                                               Side effect checklist.\                                                                                                                                                                                                        
                                                                MPH group: 9.61 ± 2.26 years).                                                                                                                                                                                                                                                                                                                                                                                                      Physiological parameters.                                                                                                                                                                                                      

  Shakibaei et al., 2015 \[[@B69-nutrients-12-01573]\]          60 ADHD (39 males),\                                                                                                                               Six weeks DBRPCT\                                                                                                      MPH: 20 mg/day\                                                                                                                                           Primary outcomes:\                                                                                                                                                                                                             Parent and Teacher ADHD-RS:\
                                                                no other neuropsychiatric comorbidities.\                                                                                                          31 subjects taking MPH\* + Ginkgo biloba.\                                                                             (10 mg/b.i.d) for subjects \<30 kg; 30 mg/day (10 mg/t d s) for subjects \>30 kg.\                                                                        Parent and Teacher ADHD-RS to measure behavior.\                                                                                                                                                                               -A significant improvement was found in inattention score and parent total rating score in supplementation group.\
                                                                Age range: 6--12 years\                                                                                                                            29 subjects taking MPH\* + Placebo.\                                                                                   G. biloba: 80 mg/day (40 mg/b.i.d) for subjects \<30 kg; 120 mg/day (40 mg/t d s) for subjects \>30 kg.\                                                  Secondary outcomes:\                                                                                                                                                                                                           - Response rate was higher in supplementation group compared to placebo based only on parent rating.\
                                                                (G. biloba group: 7.83 ± 1.21;\                                                                                                                    \*subjects took MPH before the trial.                                                                                  Placebo: similar to G. biloba tablet.                                                                                                                     C-GAS: assessment of symptoms severity as reported by clinician.\                                                                                                                                                              C-GAS:\
                                                                Placebo group: 8.41 ± 1.40 years).                                                                                                                                                                                                                                                                                                                                                                                                  Physiological parameters.\                                                                                                                                                                                                     No significant between-group difference after treatment.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Side effect checklist.                                                                                                                                                                                                         No between-group significant difference in side effects.

  Tan et al., 2016 \[[@B70-nutrients-12-01573]\]                146 ADHD (124 males), excluding syndromes, inborn errors of metabolism, brain lesions, chronic liver disease, anticoagulant/antiplatelet drugs.\   One month run in with placebo + 6 months RPCT\                                                                         TRF^a^ capsules: 200 mg/day.\                                                                                                                             VAPRS: parent-rated ADHD symptoms.\                                                                                                                                                                                            VAPRS: significant improvement in both groups.\
                                                                Age range: 6--12 years (TRF^a^ group: 9.4 ± 1.9;\                                                                                                  73 subjects taking TRF^a^ (43 subjects taking medication).\                                                            Placebo: similar to TRF ^a^.                                                                                                                              VATRS: teacher-rated ADHD symptoms.\                                                                                                                                                                                           VATRS: improvement in TRF^a^ group but not statistically significant.\
                                                                Placebo group: 9.4 ± 1.7).                                                                                                                         73 subjects taking Placebo (35 subjects taking medication).                                                                                                                                                                                                                      Side effects questionnaire.\                                                                                                                                                                                                   Side effects: non-significant differences between groups.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Tocotrienol levels (blood exams).                                                                                                                                                                                              Tocotrienol levels: higher levels in TRF^a^ group and significant correlation with the change in VAPRS.

  **(f)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Authors, year**                                             **Sample and age**                                                                                                                                 **Methodology and durations**                                                                                          **Daily doses**                                                                                                                                           **Outcome measures**                                                                                                                                                                                                           **Main results**

  Pärtty et al., 2015 \[[@B71-nutrients-12-01573]\]             75 TD children (40 males).\                                                                                                                        Six months after birth DBPCRT+ Follow-up at 13 years\                                                                  *Lactobacillus rhamnosus* GG: 1 × 10^10^ colony-forming units\\day for 4 weeks before delivery + for 6 months after delivery.                             ICD-10 diagnostic criteria for diagnoses of ADHD or Asperger syndrome (AS) filled in at follow-up.\                                                                                                                            ADHD or AS was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (*p* = 0.008).\
                                                                Age range at RCT: 0--6 months after birth.\                                                                                                        40 subjects taking *Lactobacillus rhamnosus* GG.\                                                                                                                                                                                                                                Gut microbiota: in situ hybridization (FISH) and qPCR and blood group secretor type.                                                                                                                                           The mean numbers of *Bifidobacterium* species bacteria in feces during the first 6 months of life was lower in children with ADHD or AS log cells/g than in healthy children.
                                                                Age range at follow-up: 13 years.\                                                                                                                 35 subjects taking Placebo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                Diagnoses at 13 years: 3 ADHD; 1 AS; 2 ADHD + AS.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: AA: arachidonic acid; AD: attention deficit; ADHD: attention deficit hyperactivity disorder; ADHD NOS: attention deficit hyperactivity disorder not otherwise specified; ADHD-RS: attention deficit hyperactivity disorder rating scale; AL: alpha-linolenic acid; ALC: Acetyl-L-carnitine; AMPH: d-amphetamine; AS: Asperger syndrome; ASD: autism spectrum disorder; ASQ-P: Conners' abbreviated questionnaires; ATX: atomoxetine; BRIEF: behavior rating inventory of executive function; CBCL: child behavior checklist; CD: conduct disorder; CGI-S/I: clinical global impression---severity scale/improvement scale; C-GAS: children's global assessment scale; CGQ: child health questionnaire--parent form; CHQ: child health questionnaire; CHP: compound herbal preparation; CLA: conjugated linoleic acid; CPRS-R: revised Conners' parent rating scale; CPT: continuous performance task; CTRS-R: revised Conners' teacher rating scale; DA: dopamine; DHA: docosahexaenoic acid; DHEA: dehydroepiandrosterone; DBRCT: double blind randomized controlled/clinical trial; DBRPCT: double blind randomized placebo-controlled/clinical Trial; DEN: daily essential nutrients; DIS-YPS-II Diagnostik psychischer Störungen im Kindes-und Jugendalter; DPA: docosapentaenoic acid; DSM-IV: diagnostic and statistical manual of mental disorders (4th ed.); EPA: eicosapentaenoic acid; FBRPCT: fully blinded randomized placebo-controlled trial; GLA: gamma linoleic acid; HAWIK-IV: Hamburg Wechsler Intelligence Scales for Children--IV; HD: hyperactivity disorder; HVA: homovanillic acid; IU: international unit; KITAP Test-batterie zur Aufmerksamkeitsprüfung für Kinder; KRG: Korean red ginseng; LA: linoleic acid; M: males; MOAS: modified overt aggression scale; MPH: methylphenidate; MSVA: Magallanes scale of visual attention; (f)-MRI: (functional) magnetic resonance imaging; NDG: ningdong granule; ODD: oppositional defiant disorder; OL: open label; (LC)-PUFAs: (long-chain) polyunsaturated fatty acids; PS: phosphatidylserine; QEEG TBR: quantitative electroencephalography theta/beta ratio; RPCT: randomized placebo-controlled trial; RPCCT: randomized placebo-controlled crossover trial; RPT: randomized pilot trial; RT: randomized trial; SCARED: screen for child anxiety related emotional disorders; SDQ: strengths and difficulties questionnaire; SLD: specific learning disorder; SNAP: Swanson, Nolan, and Pelham rating scale; TAP Testbatterie zur Aufmerksamkeitsprüfung; TD: typically developing; TOVA: test of variable of attention; TRF: teacher's report form; TRF^a^: tocotrienol-rich fractions; VAPRS: Vanderbilt ADHD parent rating scale (NICHQ); VATRS: Vanderbilt ADHD teacher rating scale (NICHQ); WIAT-III: Wechsler individual achievement test; WISC: Wechsler intelligence scale for children; WPREMB: weekly parent ratings of evening and morning behavior.
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###### 

Summary of sources of information that were considered in the reviewed studies.

                                         Self Rating Scales                                                                                                                                                Parent Rating Scales                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Teacher Rating Scales                                                                                                                                                                       Clinician Rated Scales                                                              Psychometric Tests                                                                                                                                                Computerized Tasks                                                                                                                                                                                                        Neurophysiological Measures
  -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  PUFAs                                  \[[@B39-nutrients-12-01573],[@B40-nutrients-12-01573]\]                                                                                                           \[[@B34-nutrients-12-01573],[@B35-nutrients-12-01573],[@B36-nutrients-12-01573],[@B37-nutrients-12-01573],[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B40-nutrients-12-01573],[@B41-nutrients-12-01573],[@B42-nutrients-12-01573],[@B43-nutrients-12-01573],[@B44-nutrients-12-01573],[@B45-nutrients-12-01573],[@B46-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B50-nutrients-12-01573],[@B51-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\]   \[[@B37-nutrients-12-01573],[@B39-nutrients-12-01573],[@B43-nutrients-12-01573],[@B44-nutrients-12-01573],[@B46-nutrients-12-01573],[@B47-nutrients-12-01573],[@B53-nutrients-12-01573]\]   \[[@B36-nutrients-12-01573],[@B41-nutrients-12-01573]\]                             \[[@B40-nutrients-12-01573],[@B42-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B52-nutrients-12-01573],[@B53-nutrients-12-01573]\]   \[[@B38-nutrients-12-01573],[@B39-nutrients-12-01573],[@B42-nutrients-12-01573],[@B43-nutrients-12-01573],[@B48-nutrients-12-01573],[@B49-nutrients-12-01573],[@B52-nutrients-12-01573]\] \[[@B53-nutrients-12-01573]\]   \[[@B38-nutrients-12-01573]\]
  Peptides and amino acids derivatives                                                                                                                                                                     \[[@B15-nutrients-12-01573],[@B17-nutrients-12-01573]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[[@B15-nutrients-12-01573],[@B17-nutrients-12-01573]\]                                                                                                                                     \[[@B21-nutrients-12-01573]\]                                                       \[[@B21-nutrients-12-01573]\]                                                                                                                                     \[[@B21-nutrients-12-01573]\]                                                                                                                                                                                             
  Single micronutrient                                                                                                                                                                                     \[[@B54-nutrients-12-01573],[@B55-nutrients-12-01573],[@B56-nutrients-12-01573],[@B57-nutrients-12-01573],[@B58-nutrients-12-01573],[@B25-nutrients-12-01573]\]                                                                                                                                                                                                                                                                                                                                                     \[[@B54-nutrients-12-01573],[@B56-nutrients-12-01573]\]                                                                                                                                     \[[@B54-nutrients-12-01573]\]                                                       \[[@B54-nutrients-12-01573]\]                                                                                                                                     \[[@B54-nutrients-12-01573]\]                                                                                                                                                                                             
  Micronutrients mix                                                                                                                                                                                       \[[@B59-nutrients-12-01573],[@B60-nutrients-12-01573],[@B61-nutrients-12-01573],[@B62-nutrients-12-01573],[@B63-nutrients-12-01573]\]                                                                                                                                                                                                                                                                                                                                                                               \[[@B59-nutrients-12-01573],[@B61-nutrients-12-01573]\]                                                                                                                                     \[[@B59-nutrients-12-01573],[@B61-nutrients-12-01573],[@B63-nutrients-12-01573]\]                                                                                                                                                                                                                                                                                                                                                                                               \[[@B59-nutrients-12-01573]\]
  Plant / herbal extracts                \[[@B64-nutrients-12-01573],[@B66-nutrients-12-01573],[@B67-nutrients-12-01573],[@B68-nutrients-12-01573],[@B69-nutrients-12-01573],[@B70-nutrients-12-01573]\]   \[[@B64-nutrients-12-01573],[@B66-nutrients-12-01573],[@B67-nutrients-12-01573],[@B68-nutrients-12-01573],[@B69-nutrients-12-01573],[@B70-nutrients-12-01573]\]                                                                                                                                                                                                                                                                                                                                                     \[[@B66-nutrients-12-01573],[@B67-nutrients-12-01573],[@B68-nutrients-12-01573],[@B69-nutrients-12-01573],[@B70-nutrients-12-01573]\]                                                       \[[@B64-nutrients-12-01573],[@B65-nutrients-12-01573]\]                                                                                                                                                                                               \[[@B64-nutrients-12-01573]\]                                                                                                                                                                                             \[[@B65-nutrients-12-01573]\]
  Probiotics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \[[@B71-nutrients-12-01573]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                   
